HDAC inhibition in FA

HDAC inhibition The biotechnology company Repligen has received MDA support for the development of an experimental treatment for FA known as histone deacetylase (HDAC) inhibition. HDAC inhibitors keep “read me” signals called acetyl groups on genes. Cells interpret these signals to mean that a gene is available to be “read” and used for protein production. HDAC inhibitors may make it possible to stimulate frataxin production despite the presence of a mutation in the gene.